<DOC>
	<DOCNO>NCT02659098</DOCNO>
	<brief_summary>The purpose study evaluate safety performance profile modify surgical procedure custom Delivery System also assess effect best correct visual acuity single subretinal administration CNTO 2476 .</brief_summary>
	<brief_title>A Study Evaluate Safety Clinical Response Subretinal Administration CNTO 2476 Participants With Geographic Atrophy</brief_title>
	<detailed_description>This multicenter ( one hospital medical school team work medical research study ) study include initial unmasked safety phase , follow randomize ( study medication assign participant chance ) , mask treatment efficacy phase participant Geographic Atrophy . The study consist 2 Phases : Open label safety Run-in Phase follow double-masked randomized treatment Phase . The duration participation study participant approximately 5 year . Efficacy evaluate 6 month , 12 month annually thereafter . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Diagnosis geographic atrophy ( GA ) secondary agerelated macular degeneration ( AMD ) confirm within 45 day prior initial randomization verify central reading center Study eye best correct visual acuity ( BCVA ) 20/80 20/800 [ Early Treatment Diabetic Retinopathy Study ( ETDRS ) log minimum angle resolution ( logMAR ) value 0.61.6 ] . The treatment eye bad BCVA Screening . If BCVA clinically equivalent , eye large GA determines study eye Participant suitable candidate ophthalmologic surgery , willing able comply surgical procedure , schedule visit , treatment plan , laboratory test study procedure . Participant meet criterion surgery center anticoagulation protocol , applicable Each participant must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study Participant history neovascular ( `` wet '' ) AMD treatment eye , include evidence retinal pigment epithelium rip evidence subretinal choroidal neovascularization fluid . In case image inconclusive , review case study site , consider history image determine eligibility . History evidence neovascular AMD fellow eye allow , antivascular endothelial growth factor ( VEGF ) therapy require least 8 week prior Screening Geographic atrophy secondary cause AMD either eye A diagnosis glaucoma intraocular pressure ( IOP ) great equal ( &gt; = ) 25 millimeter mercury ( mmHg ) treat ocular hypotensive drug . Treatment 1 drug preparation/combination , contain 1 2 ocular hypotensive active ingredient ; participant receive 2 ocular hypotensive active ingredient exclude Nuclear sclerotic cataract , cortical spoking , posterior subcapsular cataract Grade 2 per Age Related Eye Disease Study ( AREDS ) scale ophthalmologic condition reduces clarity medium , opinion investigator read center , interfere ophthalmologic examination ( example , corneal abnormality , inadequate pupillary dilation ) , surgery imaging study eye Myopia great minus ( &gt; ) 8 diopter participant great ( &gt; ) 4 diopter astigmatism , great plus ( &gt; + ) 10 diopter hyperopia</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Best Corrected Visual Acuity</keyword>
	<keyword>Geographic Atrophy</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>CNTO 2476</keyword>
</DOC>